Viatris Inc.
Viatris Inc.
Your view on VTRS
Overview
What the company does, where it operates, and who runs it.
About Viatris Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Scott Andrew Smith
- Headquarters
- 1000 Mylan Boulevard, Canonsburg, PA, US
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Scott Andrew Smith
- Headquarters
- 1000 Mylan Boulevard, Canonsburg, PA, US
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs).
The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health.
It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions.
The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies.
It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE.
The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Viatris Inc. from FRC's valuation model, read against the market price. VTRS last traded at $20.74; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Viatris Inc.. Starting points for Viatris Inc.: EPS -$0.53, beta 0.87 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Viatris Inc.. Viatris Inc. paid $0.48 per share over the last year — a 2.3% yield at the current $20.74 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Viatris Inc.. Trailing twelve-month EPS for Viatris Inc. stands at -$0.53. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$21.00
average of 9 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy4
- Hold2
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $0.61 | $0.63 | $2.58 | $2.77 |
| Low estimate | $0.58 | $0.59 | $2.52 | $2.64 |
| High estimate | $0.64 | $0.67 | $2.62 | $2.90 |
| No. of analysts | 6 | 4 | 6 | 6 |
| Year-ago EPS | $0.57 | $0.59 | -$3.001 | — |
| Growth | +6.5% | +6.8% | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $3.76B | $3.63B | $14.80B | $15.36B |
| Low estimate | $3.73B | $3.50B | $14.74B | $14.87B |
| High estimate | $3.81B | $3.70B | $14.82B | $15.77B |
| No. of analysts | 6 | 4 | 7 | 6 |
| Year-ago revenue | $3.70B | $3.52B | $14.30B | — |
| Growth | +1.6% | +3.1% | +3.5% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Viatris Inc.. Viatris Inc. has reported as a listed company since 1980. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ALKSAlkermes plcDrug Manufacturers - Specialty & Generic$7.8B
- AMPHAmphastar Pharmaceuticals, Inc.Drug Manufacturers - Specialty & Generic$1.2B
- AMRXAmneal Pharmaceuticals, Inc.Drug Manufacturers - Specialty & Generic$7.4B
- ANIPANI Pharmaceuticals, Inc.Drug Manufacturers - Specialty & Generic$1.6B
- BHCBausch Health Companies Inc.Drug Manufacturers - Specialty & Generic$3.2B
- HLNHaleon plcDrug Manufacturers - Specialty & Generic$40.4B
- OGNOrganon & Co.Drug Manufacturers - General$3.7B
More Drug Manufacturers - Specialty & Generic companies
- INLBItem 9 Labs Corp.OTC$70,181
- INMInMed Pharmaceuticals Inc.NASDAQ$9M
- INSDInstadose Pharma Corp.OTC$53,193
- IONKFIonic Brands Corp.OTC$1,592
- IPSEFIpsen S.A.OTC$9.4B
- IPSEYIpsen S.A.OTC$61.0B
- IRWDIronwood Pharmaceuticals, Inc.NASDAQ$803M
- ISCNFIsracann Biosciences Inc.OTC$1,982
- ISOLFIsodiol International Inc.OTC$4,914
- ITHUFiAnthus Capital Holdings, Inc.OTC$34M
- IVIXFInvion LimitedOTC$3M
- IVX.AXInvion LimitedASX
ETFs holding Viatris Inc.
% of the fund
- VOOVanguard S&P 500 ETF$1.0T in assets0.03%
- VTIVanguard Total Stock Market ETF$689.2B in assets0.03%
- VBVanguard Small-Cap ETF$76.9B in assets0.27%
- VBRVanguard Small-Cap Value ETF$35.1B in assets0.47%
- ADPVAdaptiv Select ETF$173M in assets5.97%
- DUSADavis Select U.S. Equity ETF$1.3B in assets5.48%
- IHEiShares US Pharmaceuticals ETF$1.7B in assets4.88%
- FTXHFirst Trust Nasdaq Pharmaceuticals ETF$1.2B in assets4.23%
Largest holders first, then the funds most concentrated in VTRS.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Viatris Inc., and how their positions are changing. At a $23.78B market value, institutional positions materially move Viatris Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Viatris Inc. executives and directors. Shares of Viatris Inc. have traded between $6.85 and $13.55 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
About this section
U.S. Senate disclosures naming Viatris Inc.. Viatris Inc. is a $23.78B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming Viatris Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Viatris Inc.. Coverage tracks Viatris Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Viatris Inc.